Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2003 May;93(5):779-85.
doi: 10.2105/ajph.93.5.779.

Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message?

Evelyn C Y Chan  1 , Sally W Vernon, Frederick T O'Donnell, Chul Ahn, Anthony Greisinger, Donnie W Aga
Affiliations
Comparative Study

Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message?

Evelyn C Y Chan et al. Am J Public Health. 2003 May.

Abstract

Objectives: This study examined knowledge about prostate-specific antigen (PSA) screening among African Americans and Whites. Because PSA screening for prostate cancer is controversial, professional organizations recommend informed consent for screening.

Methods: Men (n = 304) attending outpatient clinics were surveyed for their knowledge about and experience with screening.

Results: Most men did not know the key facts about screening with PSA. African Americans appeared less knowledgeable than Whites, but these differences were mediated by differences in educational level and experience with prostate cancer screening.

Conclusions: Public health efforts to improve informed consent for prostate cancer screening should focus on highlighting the key facts and developing different approaches for men at different levels of formal education and prior experience with screening.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
—Interaction between race/ethnicity and experience with prostate specific antigen acreening on global knowledge about prostate cancer screening: University of Texas–Houston Clinic and Kelsey-Seybold Clinic, Houston, Tex, 2001
See this image and copyright information in PMC

References

    1. Burack RC, Wood DP Jr. Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness. Med Clin North Am. 1999;83:1423–1442. - PubMed
    1. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer, II: estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med. 1997;126:468–479. - PubMed
    1. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer, I: prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med. 1997;126:394–406. - PubMed
    1. Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med. 1995;333:1401–1405. - PubMed
    1. Brawley OW. Prostate cancer screening: a note of caution. In: Thompson IM, Resnick MI, Klein EA, eds. Prostate Cancer Screening. Totowa, NJ: Humana Press; 2001:175–185.

Publication types

MeSH terms

Substances